Genocea Biosciences, Inc.
GNCADelisted Jun 2, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001457612
Genocea Biosciences, Inc. was delisted on Jun 2, 2022; its insiders filed their last Form 4 on Jun 3, 2022; 40 institutions reported holding it in 13F filings for Q1 2022, worth $42.1M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 40
- Q1 2022, −1 vs. previous quarter
- 13F value
- $42.1M
- Reported value at the end of Q1 2022
- Superinvestors holding
- 0
- At the end of Q1 2022
Superinvestors holding GNCA, Q1 2022
No superinvestor reported holding GNCA at the end of Q1 2022.
Latest insider trades
Open-market purchases and sales by Genocea Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 (view filing)4:13 PM ET | Jun 2 | 1 day | Duvall DianthaCHIEF FINANCIAL OFFICER | SSale | −1.35K | $0.06 | −$81.3 | −1.8%75.4K after | |
| Jun 3, 2022 (view filing)4:12 PM ET | Jun 2 | 1 day | Flechtner Jessica BakerChief Scientific Officer | SSale | −1.58K | $0.06 | −$94.68 | −1.7%89.0K after | |
| Jun 3, 2022 (view filing)4:11 PM ET | Jun 2 | 1 day | Clark William DPresident and CEO | SSale | −4.02K | $0.06 | −$241.38 | −1.3%304.4K after | |
| Jun 2, 2022 (view filing)4:32 PM ET | Jun 1 | 1 day | Sumer Jacquelyn LCHIEF LEGAL & COMPLIANCE OFF | SSale | −2.50K | $0.0601 | −$150.25 | −5.5%43.0K after | |
| Jun 2, 2022 (view filing)4:31 PM ET | May 31 | 2 days | Clark William DPresident and CEO | SSale | −117.2K | $0.0617 | −$7.23K | −27.5%308.4K after | |
| Jun 1, 2022 (view filing)4:11 PM ET | May 27 | 5 days | Siber GeorgeDirector | SSale | −20.4K | $0.0653 | −$1.33K | −98.8%252 after | |
| May 26, 2022 (view filing)6:32 PM ET | May 24-25 | 2 days | Walker Paul Edward10% Owner | SSale | −10.4M | $0.0723 | −$750.7K | −100.0%0 after | 2 lotsDuplicate filing |
| May 26, 2022 (view filing)6:31 PM ET | May 24-25 | 2 days | Sonsini Peter W.10% Owner | SSale | −10.4M | $0.0723 | −$750.7K | −100.0%0 after | 2 lotsDuplicate filing |
| May 26, 2022 (view filing)6:29 PM ET | May 24-25 | 2 days | Sandell Scott D10% Owner | SSale | −10.4M | $0.0723 | −$750.7K | −100.0%0 after | 2 lotsDuplicate filing |
| May 26, 2022 (view filing)6:26 PM ET | May 24-25 | 2 days | New Enterprise Associates 16, L.P. and 2 others10% Owner | SSale | −10.4M | $0.0723 | −$750.7K | −100.0%0 after | 2 lotsDuplicate filing |
Top 10 13F holders, Q1 2022
The largest institutional positions in Genocea Biosciences, Inc. at the end of Q1 2022; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 10,376,936 | $13.0M | 0.42% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 5,084,184 | $6.36M | 0.12% | 00.0% | Unchanged |
| BVF Inc | 4,012,404 | $5.02M | 0.20% | 00.0% | Unchanged |
| Commodore Capital LP | 3,079,756 | $3.85M | 0.86% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 2,576,385 | $3.22M | 0.01% | −76,589−2.9% | Reduced |
| Kingdon Capital Management, L.L.C. | 1,972,056 | $2.46M | 0.42% | 00.0% | Unchanged |
| Citadel Advisors LLC | 1,843,112 | $2.30M | 0.00% | +47,617+2.7% | Added |
| Vanguard Group Inc | 1,574,979 | $1.97M | 0.00% | +1000.0% | Added |
| Boxer Capital, LLC | 1,134,453 | $1.42M | 0.07% | 00.0% | Unchanged |
| ABG Innovation Capital Partners III GP Ltd | 375,000 | $469.0K | 32.06% | 00.0% | Unchanged |